aDepartment of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, ON, Canada bDepartment of Medicine, McMaster University, Hamilton, ON, Canada ...
Real-world data suggest nirogacestat boosts response in desmoid tumor vs standard-of-care treatment, but small cohorts leave ...
Daraxonrasib reduced mortality risk versus chemotherapy in previously treated RAS G12–mutant mPDAC (OS HR 0.40) with fewer discontinuations and delayed pain/QoL deterioration. Perioperative ...
“The results support daraxonrasib as the new standard of care for patients with previously treated metastatic PDAC,” said Brian Wolpin, MD. Daraxonrasib reduced the risk of death by 60% compared with ...
The multicenter ROADS trial was co-led by Jeffrey Weinberg, MD, professor of Neurosurgery, and Thomas H. Beckham, MD, PhD, ...
Lupin Limited (Lupin) (BSE: 500257) (NSE: LUPIN) (REUTERS: LUPIN.BO) (BLOOMBERG: LPCIN) announced that results from its Phase ...
Komodo Health claims analyses in first-line CLL showed zanubrutinib associated with lower mortality (adjusted HR 0.75) and improved TTNT (HR 0.89) versus acalabrutinib. In R/R MCL (≥2L), zanubrutinib ...
aDepartment of Clinical Research, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results